NZ333713A - Compounds for treating diseases associated with tryptase activity - Google Patents

Compounds for treating diseases associated with tryptase activity

Info

Publication number
NZ333713A
NZ333713A NZ333713A NZ33371397A NZ333713A NZ 333713 A NZ333713 A NZ 333713A NZ 333713 A NZ333713 A NZ 333713A NZ 33371397 A NZ33371397 A NZ 33371397A NZ 333713 A NZ333713 A NZ 333713A
Authority
NZ
New Zealand
Prior art keywords
alkylene
phenylene
compounds
piperidylene
aza
Prior art date
Application number
NZ333713A
Inventor
Jeffrey Mark Dener
Elaine Yee-Lin Kuo
Ken Duane Rice
Vivian Rueywen Wang
Wendy Beth Young
Original Assignee
Axys Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharm Inc filed Critical Axys Pharm Inc
Priority to NZ506614A priority Critical patent/NZ506614A/en
Publication of NZ333713A publication Critical patent/NZ333713A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds of formula 1 wherein, X5 is cis-1,5-cyclooctylene and X4 and X6 each are a covalent bond or X5 is 1,4-phenylene and X4 and X6 are (C0-1)alkylene, X1 and X9 are independently a covalent bond, C(O), NHC(O), C(O)NH, N(CH3)C(O) or S(O)2NH, X3 and X7 are independently C(O) or C(O)O, X2 and X8 are independently -X10-X11-, wherein X10 is a covalent bond or methylene and X11 is 4,1-piperidylene or 1,4-piperazinylene, R1 is -R4-X12- or -R5-X13-, wherein R4 is amidino, guanidino or methylamino, X12 is -X14-X15-X16-, wherein X15 is 1,4-phenylene or 1 ,4-piperidylene, X14 is (Cn14)alkylene and X16 is (Cn16)alkylene, wherein the sum of n14 and n16 is 0, 1 or 2, R5 is piperid-4-yl and X13 is (C2-3)alkylene and R2 is R8-X20 or R9-X21, wherein R8 is amino, methylamino or 1-iminoethyl, X20 is -X22-X23-X24-, wherein X23 is trans-1,4-cyclohexylene, 1,4-phenylene, 4,1-pyridylene, 1,4-piperidylene, X22 is (Cn22)alkylene and X24 is C(n24)alkylene, wherein the sum of n22 and n24 is 1 or 2, R9 is benzoimidazol-5-yl, imidazol-1-yl, imidazol-4-yl, 2-imidazolin-2-yl, 4-methylimidazol-1-yl, 5-methylimidazol-1-yl, 1-methylpiperid-4-yl, piperid-4-yl, piperazin-1-yl, pyrid-3-yl, 1,4,5,6-tetrahydropyrimidin-5-yl or 1,4,5,6-tetrahydro-2-dioxopyrimidin-5-yl and X21 is (C1-6)alkylene, omega-aza(C2-5)alkylene, 2-aza-3-oxotrimethylene, 3-aza-2-oxotrimethxylene, 3-oxotrimethylene, omega-thia(C2-4)alkylene or -X25-X26-X27-, wherein X26 is 1,4-phenylene, X25 is (Cn25)alkylene and X27 is (Cn27)alkylene, wherein the sum of n25 and n27 is 0 or 1 and the pharmaceutically acceptable salts, N-oxides, prodrug derivatives and protected derivatives thereof. These compounds are useful in the treatment of diseases where tryptase activity contributes to the pathology and/or symptomatology of the disease.
NZ333713A 1996-07-30 1997-07-30 Compounds for treating diseases associated with tryptase activity NZ333713A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ506614A NZ506614A (en) 1996-07-30 1997-07-30 Compounds for treating diseases associated with tryptase activity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2313996P 1996-07-30 1996-07-30
US89577297A 1997-07-17 1997-07-17
PCT/US1997/013422 WO1998004537A1 (en) 1996-07-30 1997-07-30 Novel compounds and compositions for treating diseases associated with tryptase activity

Publications (1)

Publication Number Publication Date
NZ333713A true NZ333713A (en) 2000-12-22

Family

ID=26696778

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ333713A NZ333713A (en) 1996-07-30 1997-07-30 Compounds for treating diseases associated with tryptase activity

Country Status (17)

Country Link
EP (1) EP0934293A1 (en)
JP (1) JP2001509787A (en)
KR (1) KR20000029679A (en)
CN (1) CN1073103C (en)
AU (1) AU733621B2 (en)
CA (1) CA2262542A1 (en)
CZ (1) CZ29799A3 (en)
EE (1) EE9900036A (en)
FI (1) FI990171A (en)
HU (1) HUP0003267A3 (en)
LV (1) LV12291B (en)
NO (1) NO990433L (en)
NZ (1) NZ333713A (en)
PL (1) PL331465A1 (en)
SI (1) SI9720047A (en)
SK (1) SK8599A3 (en)
WO (1) WO1998004537A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
AU2723099A (en) * 1998-02-06 1999-08-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
PT1060175E (en) * 1998-02-06 2005-03-31 Max Planck Ges Ford Wissenscha TRIPTASE INHIBITORS
IL141654A0 (en) * 1998-09-04 2002-03-10 Byk Gulden Lomberg Chem Fab Pyranose derivatives and pharmaceutical compositions containing the same
KR20020016942A (en) 1999-08-10 2002-03-06 빅 굴덴 롬베르크 케미쉐 파브릭 게엠베하 Diazocin-dione derivatives and their uses tryptase inhibitors
EP1216236A1 (en) * 1999-09-14 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Tryptase inhibitors
WO2001036386A1 (en) * 1999-11-17 2001-05-25 Sumitomo Pharmaceuticals Co., Ltd. Diabetic remedy containing dipiperazine derivative
DE19955476A1 (en) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basic compounds as tryptase inhibitors, process for their preparation and their use as medicaments
US6815557B2 (en) 1999-12-20 2004-11-09 Altana Pharma Ag Tryptase inhibitors
AU783217B2 (en) * 1999-12-20 2005-10-06 Altana Pharma Ag Tryptase inhibitors
PT1358182E (en) * 2001-01-31 2004-12-31 Altana Pharma Ag DERIVATIVES OF DIAZOCINES AND THEIR USE AS TRIPTASE INHIBITORS
AU2002253035B8 (en) 2001-02-21 2008-02-21 Altana Pharma Ag Tryptase inhibitors
DE60220504T2 (en) 2001-02-21 2008-02-14 Nycomed Gmbh TRYPTASEHEMMER
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
US20040087792A1 (en) * 2001-03-15 2004-05-06 Thomas Martin Tryptase-inhibitors
ES2296956T5 (en) 2001-06-11 2011-07-12 Xenoport, Inc. GABA ANALOGUE PROPHARMACS, COMPOSITIONS AND THEIR USES.
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
DE60216920T2 (en) 2001-06-19 2007-11-15 Nycomed Gmbh Tryptase INHIBITORS
BRPI0517227B8 (en) 2004-11-04 2021-05-25 Xenoport Inc 1-{[alpha-isobutanoyloxyethoxy)carbonyl]amino methyl}-1-acetic acid extended-release tablet, and use of the tablet
TWI432188B (en) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases
KR101335118B1 (en) 2008-12-19 2013-12-05 메르츠 파마 게엠베하 운트 코. 카가아 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
FR3038605B1 (en) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne VICINAL PRIMARY DIAMINS ASSOCIATED WITH CHELATING MOTIFS OF METALS AND / OR FREE RADICALS, ACTIVE AGAINST CARBONYL AND OXIDIZING STRESSES AND THEIR USE
JP7373191B2 (en) * 2017-05-12 2023-11-02 国立研究開発法人理化学研究所 Class A GPCR-binding compound variants

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
KR100309616B1 (en) * 1993-03-12 2002-02-28 추후제출 Compositions and Methods for the Treatment of Immune Mediated Inflammatory Diseases
WO1995032945A1 (en) * 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
HUT77770A (en) * 1994-09-23 1998-08-28 Axys Pharmaceuticals, Inc. Compositions and methods for treating mast-cell inflammatory condition
PL322409A1 (en) * 1995-03-24 1998-01-19 Arris Pharm Corp Reversible protease inhibitors
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Also Published As

Publication number Publication date
NO990433L (en) 1999-03-25
CZ29799A3 (en) 1999-06-16
LV12291A (en) 1999-06-20
HUP0003267A3 (en) 2002-02-28
AU3967097A (en) 1998-02-20
KR20000029679A (en) 2000-05-25
AU733621B2 (en) 2001-05-17
HUP0003267A2 (en) 2001-06-28
FI990171A (en) 1999-03-23
NO990433D0 (en) 1999-01-29
LV12291B (en) 2000-04-20
JP2001509787A (en) 2001-07-24
EP0934293A1 (en) 1999-08-11
CN1226892A (en) 1999-08-25
CA2262542A1 (en) 1998-02-05
PL331465A1 (en) 1999-07-19
WO1998004537A1 (en) 1998-02-05
FI990171A0 (en) 1999-01-29
SI9720047A (en) 1999-08-31
CN1073103C (en) 2001-10-17
EE9900036A (en) 1999-08-16
SK8599A3 (en) 2000-03-13

Similar Documents

Publication Publication Date Title
NZ333713A (en) Compounds for treating diseases associated with tryptase activity
AU2003298094A8 (en) Medicinal arylethanolamine compounds
KR100239168B1 (en) Heterocyclic amines useful in the therapy of athma and inflammation of the respiratory tracts
AP2088A (en) Phenethanolamine derivatives for treatment of respiratory diseases
IT1254704B (en) NON-WOVEN FABRIC ESSENTIALLY CONSTITUTED FROM DERIVATIVES OF HYALURONIC ACID
NO20053742L (en) Tri (cyclo) -substituted amide compounds
MXPA04002405A (en) Phenethanolamine derivatives for treatment of respiratory diseases.
EG25822A (en) Quinolinyl-pyrrolopyrazoles
DE60230297D1 (en) CONTOURED FRAME FOR A KNEE ORTHESIS
JO2353B1 (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
UA74346C2 (en) Aminodicarboxylic acids derivatives, use thereof and a medicament
TW200635903A (en) Therapeutic agents
HK1013993A1 (en) Novel carbamates and ureas as modifiers of multi-drug resistance
JO2475B1 (en) Glucokinase Activators
ES2132393T3 (en) GUANIDINE DERIVATIVES USEFUL IN THERAPEUTICS.
GEP20074024B (en) Polyalkylene glycol comprising a radical for conjugation of biologically active compound
HUT57044A (en) Process for producing phrmaceutical compositions having n-neuropeptide antagonistic effect and comprising imidazolyl alkylguanidine derivatives
PL313941A1 (en) Alkoxyalkyl carbamates of imidazo /1,2-a/ pyrimidines
GB2378180B8 (en) New purine derivatives
ZA200110540B (en) Novel diphenyl-piperidine derivate.
TW200509933A (en) Therapeutic agents
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
HUP0300615A2 (en) Therapeutic agents
DE69227583D1 (en) ARYLMORPHOLINE, PRODUCTION AND USE
HK1045809B (en) Utilization of polycyclic 2-amino-thiazole systems in the production of medicaments for prophylaxis or treatment of obesity

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)